Text Size
   
YouCMSAndBlog Module Generator Wizard Plugin

SRBCF

SRBCF Today's Biotech Breakout Play

Company: Sirona Biochem Corp.

OTCBB Symbol: SRBCF

Current PPS: $0.105 <--- Ground Level Entry Point!                 

TSX-V Symbol: SBM

Current PPS: $0.10

Outstanding Shares: 65M

Float: 5.M<===Extremely Low Float!!!

Website: www.sironabiochem.com

About the Company:

Sirona Biochem Corp. (PINKSHEETS: SRBCF) (TSX-V: SBM) founded in 2009, is a biotechnology company developing diabetes and obesity therapeutics, cancer vaccine antigens, cosmeceuticals and biological ingredients. SRBCF utilizes their proprietary chemistry technique to improve pharmaceutical properties of our carbohydrate-based molecules.

SRBCF has developed a fluorination technique to maintain the integrity of carbohydrate-based molecules even after exposure to enzymes known to typically negatively affect them. This proprietary technique has allowed SRBCF to explore the immense opportunities carbohydrate-based molecules can offer.

SRBCF's focus is centered around three high-valued programs(Therapeutics, Cosmeceuticals, and Biological Ingredients) which were selected based on SRBCF's research expertise in the area, market opportunities, development timelines and maximum Return On Investment (ROI).

The advantages of SRBCF‘s improved carbohydrate based molecules within each industry can be found in the chart below:


Member's please check out SRBCF on youtube for an in depth explanation of how their innovative technology will rock the pharmaceutical world!!

SRBCF has made major headlines twice today.

This morning it was announced that SRBCF had completed a pivotal proof of concept study of its biological inducer for recombinant protein manufacturing.

And just and hour ago SRBCF announced after market news regarding the appointment of organic chemistry expert Professor Pierre Vogel, fluorine chemistry expert Dr. Bernard Langlois and carbohydrate chemistry expert Dr. Eric Leclerc to the Scientific Advisory Board of its subsidiary TFChem.

The full press releases for both these major announcements can be found below

We are urging all members to keep a close eye on SRBCF tomorrow and to be ready to put your buy orders in early at 9:30am EST.

Be sure to check your inbox early tomorrow at 7am for PSL's full in depth profile on SRCBF.

As always remember to follow PennyStockLocks on Facebook and Twitter for the latest news and updates on SRBCF.

Sirona Biochem Appoints Three Chemistry Experts to Subsidiary Scientific Advisory Board
4:31p ET February 14, 2012 (Market Wire)

Sirona Biochem Corp. (TSX VENTURE: SBM)(PINKSHEETS: SRBCF)(FRANKFURT: ZSB), a biotechnology company specializing in carbohydrate chemistry technology, announced today it has appointed organic chemistry expert Professor Pierre Vogel, fluorine chemistry expert Dr. Bernard Langlois and carbohydrate chemistry expert Dr. Eric Leclerc to the Scientific Advisory Board of its subsidiary, TFChem.

"These respected chemists will bring a tremendous amount of scientific insight to our research efforts," said Dr. Howard Verrico, President and CEO of Sirona Biochem. "This expertise will help to streamline our processes in compound development, selection and formulation and give us a better understanding of the compounds' commercial relevance," Dr. Howard Verrico added.

Biography of Professor Pierre Vogel

Dr. Pierre Vogel has been a Professor of Organic Chemistry at the Ecole Polytechnique Federale de Lausanne, Switzerland since 2001. In 1969, he completed his Ph.D under the supervision of Prof. H. Prinzbach at the Institute of Organic Chemistry, University of Lausanne. Dr. Vogel spent two years at Yale University, New Haven, Connecticut, USA with Prof. Martin Saunders, Prof. J. A. Berson, K. A. Wiberg and P.v.R. Schleyer (Princeton Universtiy). He then worked as a Research chemist at Syntex S.A., in Mexico with Prof. P.Crabbe before returning to the University of Lausanne in 1973. As of 1977 he became Professor of organic chemistry at the University of Lausanne. In 1991 he was Vice-Chairman of the Institute of organic Chemistry, University of Lausanne until 2001. He was also a part-time graduate school teacher at the Universities of Rouen and Caen from 1991 to 1993 and part-time professor at Ecole Polytechnique de Palaiseau from 1993-2000. Dr. Vogel has authored over 520 publications in referred journals.

Biography of Dr. Bernard Langlois

Dr. Bernard Langlois is a scientific expert in the area of organic fluorine chemistry with more than 40 years of academic experience. Until recently, he was the Director of the SERCOF laboratory at the University of Lyon in France as well as the Research Director for CNRS at the Universite de Claude Bernard. D. Langlois has been involved in organic fluorine chemistry since 1970, when he joined the research team of the Rhone-Poulenc Co. His interest is directed to all aspects of organic fluorine chemistry; aromatic and aliphatic compounds, fluorination and trifluoromethylation techniques, as well as functionalization of fluorinated substrates. During his career, he developed new methods for performing radical perfluoroalkylation using "Halons" or sodium trifluoromethanesulfinate, mild nucleophilic trifluoromethylation with fluoral hemiaminals or hydroxytrifluoroacetamides, as well as nucleophilic trifluoromethoxylation. He was also involved in work on a new route to triflic acid from bromotrifluoromethane. Dr. Langlois is the author of more than 90 articles, 9 book chapters, 33 patents, 60 poster presentations, 69 oral presentations and 39 invited and plenary lectures in national and international events. Dr. Langlois received his PhD from the University of Lyon (France).

Biography of Dr. Eric Leclerc

Dr. Eric Leclerc is currently a Centre Nationale de la Recherche Scientifique (CNRS) Researcher at the Institut Charles Gerhardt in France. In this role, Dr. Leclerc is responsible for the development of new tools for the synthesis of fluoroolefins and metabolically stable, fluorinated glycomimetics as analogues of glycoconjugate with high therapeutic potential. Prior to this role he was a Researcher at the Institut National des Sciences Appliquees (INSA) de Rouen, also in France, where he was responsible for the development of fluorinated glycomimetics and synthesis of chiral ligands for asymmetric catalysis. Previous positions include a post-doctoral role at the University of Hawaii at Manoa and a PhD position at the Universite Pierre et Marie Currie. Dr. Leclerc has authored more than 20 publications and has given several presentations in the area of fluorinated glycomimetics. He received his PhD and Masters in organic chemistry from the Universite Pierre et Marie Currie in 2001 and 1997, respectively.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging cosmeceuticals and biological ingredients. We are applying a proprietary chemistry technique to improve the pharmaceutical properties of our carbohydrate-based molecules. For more information visit www.sironabiochem.com.

Sirona Biochem Announces Results in Key Study for Biological Inducer
9:05a ET February 14, 2012 (Market Wire)

Sirona Biochem Corp. (TSX VENTURE: SBM)(PINKSHEETS: SRBCF)(FRANKFURT: ZSB) (the "Company"), a biotechnology company, announced today it has completed a pivotal proof of concept study of its biological inducer for recombinant protein manufacturing.

In the study, Sirona Biochem's inducer produced more protein compared to a leading commercially available inducer at the same concentration. In addition, Sirona Biochem's compound induced synthesis of a soluble recombinant protein in Escherichia coli for up to 24 hours.

"We believe we are on track to producing an inducer that is more stable, can be stored at room temperature and can improve protein yields for recombinant protein manufacturers, which could be particularly useful in producing insulin," said Sean Cunliffe, Chief Business Officer of Sirona Biochem. "The results of this study further validates our proprietary chemistry platform and its potential in improving upon existing carbohydrate molecules," Mr. Cunliffe added.

Inducers are carbohydrates which trigger recombinant protein production. The quality of the inducer is key to the production process and can affect the quality and yield of the protein. Current inducers, because they are carbohydrates, are metabolically unstable, and require special handling conditions.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.

Enhanced by Zemanta

FREE Stock Alerts

 

Partner Sites

Follow Us On

As Seen On...

IHUB

MarketWatch

Yahoo Finance

Google Finance

MSN

Penny Stock Picks